Compare Abbott Laboratories (ABT) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Raymond James Financial, Inc. — how do they compare? Abbott Laboratories trades at $109.64 (market cap $187.95B), while Raymond James Financial, Inc. trades at $179.97 (market cap $34.63B). The key difference: Abbott Laboratories is far larger — about 5.4× Raymond James Financial, Inc.'s market cap, and Abbott Laboratories pays the higher dividend (2.32%). Which is the better fit depends on your goals.
| ABT | RJF | |
|---|---|---|
Market Cap | $187.95B | $34.63B |
Sector | Health | Financials |
52-Week High | $136.62 | $180.55 |
52-Week Low | $82.57 | $140.89 |
Enterprise Value | $214.96B | — |
Dividend Yield | 2.32% | 1.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
Raymond James Financial (RJF) trades at $181.18, up 1.17% with strong technical momentum including a golden cross formation. The company reported record Q3 2026 earnings of $3.14 per share, beating estimates by 7.2%, driven by 16% revenue growth to $3.93 billion. Analyst consensus remains positive with 44% buy ratings and a $183.75 price target, slightly above current levels. The stock shows bullish moving average signals while RSI indicates potential overbought conditions near-term.
RJF demonstrates solid fundamental growth with consistent earnings beats and expanding profit margins, though valuation appears fair at current levels. Key risks include market sensitivity to capital markets performance and competitive advisor recruitment landscape. The technical setup suggests near-term resistance around $182, while fundamental strength supports longer-term upside potential if revenue momentum continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
